Evidence map›Paper›PMID 27895488›Full record

ReviewVascular health and risk management2016

Advances in the management of heart failure: the role of ivabradine.

Ursula Müller-Werdan, Georg Stöckl, Karl Werdan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vascular health and risk management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Ursula Müller-WerdanCharité - Universitätsmedizin Berlin; Protestant Geriatric Centre, Berlin.
Georg StöcklDepartment of Medical Affairs, Servier Deutschland GmbH, Munich.
Karl WerdanDepartment of Medicine III, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Charité - Universitätsmedizin Berlin · DEMartin Luther University Halle-Wittenberg · DEServier (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A high resting heart rate (≥70-75 b.p.m.) is a risk factor for patients with heart failure (HF) with reduced ejection fraction (EF), probably in the sense of accelerated atherosclerosis, with an increased morbidity and mortality. Beta-blockers not only reduce heart rate but also have negative inotropic and blood pressure-lowering effects, and therefore, in many patients, they cannot be given in the recommended dose. Ivabradine specifically inhibits the pacemaker current (funny current,

Indexed as

Action PotentialsAgedAged, 80 and overAge FactorsAnimalsAnti-Arrhythmia AgentsBenzazepinesBiological ClocksChronic DiseaseCyclic Nucleotide-Gated Cation ChannelsDrug Therapy, CombinationHeart Conduction SystemHeart FailureHeart RateHumansIvabradineAnti-Arrhythmia AgentsBenzazepinesCyclic Nucleotide-Gated Cation ChannelsIvabradineendotoxinheart failureheart rateheart rate variabilityIf inhibitorivabradinepacemaker current inhibitor

Identifiers

PMID27895488
PMCPMC5118024
OpenAlexW2551038843

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.